Trial Profile
CAEL101-203: A Phase 2, Open-label, Multicenter Dose Selection Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jan 2024
Price :
$35
*
At a glance
- Drugs Anselamimab (Primary) ; Bortezomib; Cyclophosphamide; Daratumumab; Dexamethasone
- Indications Amyloid light-chain amyloidosis
- Focus Adverse reactions
- Sponsors Alexion AstraZeneca Rare Disease; Caelum Biosciences
- 12 Dec 2023 Results (n=25 )assessing safety, tolerability, and biomarker data after 110 weeks of treatment with CAEL-101, administered initially with cyclophosphamide-bortezomib-dexamethasone and daratumumab, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 29 Nov 2023 According to an AstraZeneca media release, 24-month results from this study will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, 9 to 12 December 2023.
- 27 Nov 2023 Status changed from active, no longer recruiting to completed.